Stryker (SYK) Competitors

Stryker (NYSE:SYK) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, community ranking, profitability and media sentiment.

Do institutionals and insiders hold more shares of SYK or ABT?

77.1% of Stryker shares are owned by institutional investors. Comparatively, 75.2% of Abbott Laboratories shares are owned by institutional investors. 5.5% of Stryker shares are owned by company insiders. Comparatively, 0.5% of Abbott Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Does the media favor SYK or ABT?

In the previous week, Abbott Laboratories had 36 more articles in the media than Stryker. MarketBeat recorded 71 mentions for Abbott Laboratories and 35 mentions for Stryker. Stryker's average media sentiment score of 1.37 beat Abbott Laboratories' score of 1.32 indicating that Stryker is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stryker	29 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abbott Laboratories	58 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Which has more volatility and risk, SYK or ABT?

Stryker has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500.

Does the MarketBeat Community prefer SYK or ABT?

Abbott Laboratories received 9 more outperform votes than Stryker when rated by MarketBeat users. Likewise, 69.72% of users gave Abbott Laboratories an outperform vote while only 64.76% of users gave Stryker an outperform vote.

Company	Underperform	Outperform
Stryker	Outperform Votes 926 64.76%	Underperform Votes 504 35.24%
Abbott Laboratories	Outperform Votes 935 69.72%	Underperform Votes 406 30.28%

Which has preferable earnings and valuation, SYK or ABT?

Abbott Laboratories has higher revenue and earnings than Stryker. Abbott Laboratories is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stryker	$20.50B	7.14	$3.17B	$9.33	41.15
Abbott Laboratories	$40.11B	4.91	$5.72B	$3.29	34.48

Do analysts rate SYK or ABT?

Stryker currently has a consensus price target of $405.80, indicating a potential upside of 5.70%. Abbott Laboratories has a consensus price target of $131.57, indicating a potential upside of 15.97%. Given Abbott Laboratories' higher probable upside, analysts clearly believe Abbott Laboratories is more favorable than Stryker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stryker	0 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.81
Abbott Laboratories	0 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.73

Is SYK or ABT more profitable?

Stryker has a net margin of 16.34% compared to Abbott Laboratories' net margin of 13.99%. Stryker's return on equity of 23.07% beat Abbott Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stryker	16.34%	23.07%	11.04%
Abbott Laboratories	13.99%	20.18%	10.84%

Is SYK or ABT a better dividend stock?

Stryker pays an annual dividend of $3.36 per share and has a dividend yield of 0.9%. Abbott Laboratories pays an annual dividend of $2.20 per share and has a dividend yield of 1.9%. Stryker pays out 36.0% of its earnings in the form of a dividend. Abbott Laboratories pays out 66.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has increased its dividend for 32 consecutive years.

Summary

Stryker beats Abbott Laboratories on 14 of the 21 factors compared between the two stocks.